Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:1456-1463
doi: 10.1161/CIRCULATIONAHA.106.649863
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patterson, C.
Right arrow Articles by Willis, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patterson, C.
Right arrow Articles by Willis, M. S.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Heart Diseases
Related Collections
Right arrow Contractile function
Right arrow Congestive

(Circulation. 2007;115:1456-1463.)
© 2007 American Heart Association, Inc.


Basic Science for Clinicians

The Bitter End

The Ubiquitin-Proteasome System and Cardiac Dysfunction

Cam Patterson, MD; Christopher Ike, MD; Park W. Willis, IV, MD; George A. Stouffer, MD; Monte S. Willis, MD, PhD

From the Carolina Cardiovascular Biology Center and Division of Cardiology, University of North Carolina, Chapel Hill.

Correspondence to Cam Patterson, MD, Division of Cardiology and Carolina Cardiovascular Biology Center, University of North Carolina at Chapel Hill, 8200 Medical Biomolecular Research Building, Chapel Hill, NC 27599-7126. E-mail cpatters{at}med.unc.edu

Many elements contribute to congestive heart failure: changes in perfusion, hemodynamic stresses, alterations in calcium metabolism, and dysregulation of cell signaling pathways. Intervention in these processes forms the basis for current heart failure therapies. Nevertheless, heart failure is primarily a disease of wear and tear; despite everything we know about cardiac physiology and the clinical manifestations of heart failure, only in rare instances does therapy for heart failure normalize cardiac function. Proteins are especially prone to the forces of wear and tear in the heart because they are the primary mechanisms for stress sensing and force generation. Recent evidence supports a role for protein damage and impaired clearance of damaged proteins in the pathophysiology of human heart failure syndromes. The process of monitoring and protecting cardiac cells from accumulation of damaged proteins is known as protein quality control, and the molecular chaperone and ubiquitin-proteasome systems are the primary effectors of this process. Insights from protein quality-control strategies may lead to new concepts about prevention and treatment of human heart failure. This review provides a general overview of these pathways and their known and postulated roles in human heart failure syndromes, with a focus on providing a clinically oriented understanding of these fundamental mechanisms.


Key Words: heart failure • hypertrophy • ischemia • proteins • apoptosis




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
O. Tsukamoto, T. Minamino, and M. Kitakaze
Functional alterations of cardiac proteasomes under physiological and pathological conditions
Cardiovasc Res, September 4, 2009; (2009) cvp282v2.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. W. Dorn II
Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling
Cardiovasc Res, February 15, 2009; 81(3): 465 - 473.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Liu, H. Zheng, M. Tang, Y.-C. Ryu, and X. Wang
A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome
Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2541 - H2550.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. X. Fang, F. Dong, D. P. Thomas, H. Ma, L. He, and J. Ren
Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1206 - H1215.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
V. Croons, W. Martinet, A. G. Herman, and G. R. Y. De Meyer
Differential Effect of the Protein Synthesis Inhibitors Puromycin and Cycloheximide on Vascular Smooth Muscle Cell Viability
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 824 - 832.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Herrmann, S. M. Soares, L. O. Lerman, and A. Lerman
Potential Role of the Ubiquitin-Proteasome System in Atherosclerosis: Aspects of a Protein Quality Disease
J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2003 - 2010.
[Abstract] [Full Text] [PDF]